View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Mersana Therapeutics Provides Business Update and Announces Second Qua...

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

CLEAR is Under Construction in Epic Toolbox in Identity Verification f...

CLEAR is Under Construction in Epic Toolbox in Identity Verification for EpicCare Link to Streamline Provider Access, Boost Security Integration will bring CLEAR’s identity verification platform to community-based providers, enhancing account creation and recovery workflows in EpicCare Link NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), the secure identity company, announced today that CLEAR1 is category, expanding its identity verification capabilities to support community health providers and affiliated staff. By continuing to integrate with Epic, CLEAR1 will bring se...

Matthew Weiss ... (+2)
  • Matthew Weiss
  • Scott Devitt

Travel Getting Toppy; Neutral, $130 PT

Figure 1. 2Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 2Q results and provided an in-line outlook for 3Q. Nights and Experiences booked growth in 2Q of +7.4% Y/Y was ~80bps above Street estimates. Revenue and adj. EBITDA were ahead of estimates by

 PRESS RELEASE

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on Au...

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To...

Matthew Weiss ... (+2)
  • Matthew Weiss
  • Scott Devitt

Bookings Strength Persists; Neutral, $33PT

Figure 1. 2Q25 Results vs. ExpectationsSource: Company reports, Wedbush estimates, FactSet consensusClear reported 2Q results ahead of estimates. Bookings growth of +13.1% Y/Y in 2Q was approximately 260bps above consensus, and Clear delivered adj. EBITDA of $60.1mm (27.4% margin), exceeding the St

 PRESS RELEASE

CLEAR Announces Second Quarter 2025 Financial Results

CLEAR Announces Second Quarter 2025 Financial Results NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clear Secure, Inc. (NYSE: YOU), the secure identity platform, has released financial results for the second quarter of fiscal year of 2025 on its Investor Relations website at . Second Quarter Financial Highlights(percentage change is expressed as year-over-year, unless otherwise specified) Revenue of $219.5 million was up 17.5%; Total Bookings of $222.9 million were up 13.1%Operating income of $42.6 million, representing a 19.4% Operating income marginNet income of $37.9 million, represent...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

CLEAR Joins White House and CMS Effort to Power an Interoperable, Secu...

CLEAR Joins White House and CMS Effort to Power an Interoperable, Secure Digital Health Ecosystem As the IAL2 identity layer for major healthcare partners, CLEAR supports CMS’s nationwide initiative to modernize care through trusted, interoperable technologies NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), the secure identity platform, is participating in the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem initiative, a nationwide effort to deliver a more connected, patient-centered healthcare system. CLEAR was proud to stand alongside government, h...

Matthew Weiss ... (+2)
  • Matthew Weiss
  • Scott Devitt

Now Arriving: July '25 Online Travel Trends

Key Findings:US hotel RevPAR growth has averaged -0.4% Y/Y in 2Q, from +2% Y/Y in 1Q and +4% Y/Y in 4Q24. Growth fell ~1% Y/Y in June after flat Y/Y growth (~0%) in both May and April. Trends are slightly more positive on a 2-year stacked basis, with RevPAR growth averaging +1% Y/Y in 2Q, consisten

 PRESS RELEASE

Alpine Income Property Trust Reports Second Quarter 2025 Operating and...

Alpine Income Property Trust Reports Second Quarter 2025 Operating and Financial Results WINTER PARK, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”), an owner and operator of single tenant net leased commercial income properties, today announced its operating results and earnings for the three and six months ended June 30, 2025. “We continued to effectively execute our strategy focused on accretive capital recycling and have supplemented it with opportunistic common stock repurchases during the first half ...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company’s common stock (the Reverse Stock Split), effective at 5:00 p.m. Eastern Time on July 25, 2025. The Reverse Stock Split was approved by the company’s stockholders at the com...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch